Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616923 · ClinicalTrials.gov registry record · Phase 1
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
A Phase 1 study, sponsored by Albany Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05616923 is a Phase 1 study that has completed, run by Albany Research Institute. The registered enrollment target is 12 participants.
The verdict
NCT05616923, a Phase 1 study, has completed, sponsored by Albany Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea
Interventions
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05616923
The ClinicalTrials.gov registry entry for NCT05616923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany Research Institute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trametinib is the first listed.
NCT05616923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05616923 about?
NCT05616923 is a clinical study titled "Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea". This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea
What is the current status of trial NCT05616923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-11-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT05616923?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT05616923?
This trial is sponsored by Albany Research Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.